צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים anavex.com (AVXL)

Anavex Life Sciences (AVXL) develops small molecules to combat dementia and Parkinson's disease, leveraging long-term demand. The quarterly EPS growth history visualizes profit dynamics, where 154.40 shows the value of this parameter. Blarcamesine trials and the search for partners drive growth, while the environmental profile is limited by strict adherence to laboratory disposal regulations.
פילוחי נתונים אנליטיים מרוכזים עבור Anavex Life Sciences (AVXL)

This indicator reflects the percentage change in earnings per share compared to the same period last year. The metric measures capital generation efficiency by stripping the financial result of the influence of total shares outstanding. For Anavex Life Sciences (AVXL), which develops drugs for neurodegenerative diseases, this calculation captures the transition stage from R&D expenditures to monetization. By analyzing the quarterly EPS trend, an investor can assess the business's scaling pace.